The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.00
Bid: 39.00
Ask: 41.00
Change: 5.00 (14.29%)
Spread: 2.00 (5.128%)
Open: 35.00
High: 40.50
Low: 35.00
Prev. Close: 35.00
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal

Tue, 02nd Jan 2024 10:05

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

LungLife AI Inc, up 36% at 62.33 pence, 12-month range 19.00p-141.10p. The developer of clinical diagnostic solutions designed to address the early detection of lung cancer announces the successful validation of its LungLB test for indeterminate lung nodules. This is from a "prospective, multi-site clinical study in the clinically important small nodules patient group". The LungLB test is a blood-based tool used by clinicians to help with earlier diagnosis of lung cancer nodules. The diagnostic demonstrates a positive predictive value of 81% in distinguishing benign from cancerous lung nodules in patients with nodules smaller than 15 millimetres. This surpasses the current clinical standard of around 60%. According to LungLife, the results are sufficient for publication and the execution of its commercial programme for LungLB. The initial launch will be through an early access program offered from its California laboratory in the first quarter of 2024.

----------

Sareum Holdings PLC, up 19% at 71.00p, 12-month range 50.00p-149.00p. The pharmaceutical company's co-development partner CRT Pioneer Fund enters into a development and commercialisation licence for SRA737 with an unnamed US biopharmaceutical company. SRA737 is a clinical-stage oral, selective checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Sareum says an immediate upfront payment of USD500,000 is due to CRT Pioneer Fund, while an additional fee made up of up to USD1.0 million cash and 500,000 shares in the licensee company may be payable upon the sooner 12 months following the signing of the licencing agreement, or if the licensee company achieves certain commercial and material financing objectives. A further announcement regarding any future income, including any shares which may be issued, will be made "at the appropriate time".

----------

AIM - LOSERS

----------

Plexus Holdings PLC, down 15% at 17.94p, 12-month range 1.60p-31.40p. The oil and gas engineering services business completes an agreement with SLB to replace an existing surface production wellhead licence with a new licence over a wider field of use for USD5.2 million in cash. It says SLB acquires a perpetual royalty free license for Pos-Grip technology and HG seal technology plus any improvements, enhancements, or derivatives to the technology for surface wellhead production applications for all pressure and size ranges. Plexus says the licence scope includes oil and gas production and storage applications, as well as carbon dioxide storage and hydrogen storage, alongside water and cuttings reinjection. Plexus Chief Executive Officer Ben van Bilderbeek says: "This new licence agreement is a further validation of Plexus' [intellectual property] by this leading energy technology company and recognises the contribution our leak-proof POS-GRIP wellhead equipment can make to the oil and gas industry's [environmental, social and governance] and net zero goals."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
26 Feb 2014 12:01

Sareum Shares Drop As Pretax Loss Widens

LONDON (Alliance News) - Shares in Sareum Holdings PLC slid 12% Wednesday as its pretax loss widened in the half-year ended December 31, 2013. The specialist cancer drug discovery and development business posted a pretax loss of GBP375,000, widened from GBP305,000 in the previous year, due

Read more
22 Jan 2014 10:27

Sareum Receives Patent As It Progresses Cancer Treatment To Trials

LONDON (Alliance News) - Sareum Holdings PLC said Wednesday that it had received a patent from the US Patent and Trademark Office for one of the inventions associated to its CHK1 cancer treatment programme. The patent covers compounds developed by Sareum and Cancer Research UK-funded scient

Read more
2 Dec 2013 14:17

Sareum Holdings does cancer drug deal in China

Cancer drug developer Sareum Holdings has signed a deal with a Chinese medical university to progress its Aurora+FLT3 cancer programme. Sareum has granted the Hebei Medical University Biomedical Engineering Center exclusive rights to carry out pre-clinical and clinical studies within Greater China

Read more
1 Nov 2013 12:52

UK WINNERS & LOSERS: Vodafone Up But Meggitt Slides After Warning

Read more
1 Nov 2013 12:34

Sareum raises funds for further drug development

Sareum Holdings, a cancer drug discovery and development business, has placed 278.5m shares at 0.6p each, it announced Friday. The group raised a conditional £1.67m before expenses from the placing, which it said was oversubscribed. The proceeds of the placing will provide funds to facilitate the

Read more
1 Nov 2013 10:48

CORRECT: Sareum Slides After Placing To Raise Funds For Development Programmes

Read more
1 Nov 2013 10:17

Sareum Slides After Placing To Raise Funds For Development Programmes

Read more
24 Sep 2013 07:35

Sareum Holdings In Co-Development Deal For Cancer Treatment

Read more
22 Apr 2013 08:06

Sareum Holdings and SRI International develop drug for inflammatory diseases

Cancer drug discovery business Sareum Holdings has entered into a co-development agreement with research institute SRI International. The two have joined forces to advance Sareum's Tyrosine Kinase 2 (TYK2) small molecule drug discovery programme for readiness in human clinical trials. Research wi

Read more
18 Feb 2013 08:21

Sareum shares fall following interims and research update

Shares in AIM-listed Sareum Holdings, the specialist cancer drug discovery business, fell sharply on Monday morning after the company unveiled its half yearly results alongside a research update. Cash at bank as of December 31st fell 28% to £380,000 and the company reported a loss on ordinary activ

Read more
7 Feb 2013 08:27

Sareum share price climbs on US patent grant announcement

The share price of AIM-listed specialist cancer drug discovery business Sareum Holdings jumped sharply on Thursday after the company announced that a patent was due to be awarded in the US for one of its key drug discovery inventions. The patent, which is expected on February 19th, relates to compo

Read more
12 Dec 2012 10:40

Sareum share price plummets ahead of AGM

The likelihood that specialist cancer drug discovery business Sareum will conclude a deal to commercialise a research programme this year has fallen, according to an announcement made ahead of its annual general meeting (AGM) on Wednesday morning. During the AGM, Dr. Paul Harper, the company's Chai

Read more
10 Sep 2012 14:37

Small caps round-up: Sareum, Lonrho, FFastFill

Sareum, a specialist cancer drug discovery business, has entered into a four million pound Standby Equity Distribution Agreement (SEDA) with YA Global Master, an investment fund to provide a flexible source of future funding to the company to support its on-going drug research activities. It will a

Read more
7 Aug 2012 11:25

Small caps round-up: YouGov, Sareum and InterQuest...

Environmental Recycling Technologies, which owns the rights to the Powder Impression Moulding (PIM) process which is capable of converting mixed waste plastics into commercially viable products, has confirmed that its US parent application, entitled 'Process for Forming Plastic, Apparatuses for Form

Read more
19 Jul 2012 12:07

Small caps round-up: Byotrol, sareum, KDD ...

Byotrol, an anti-microbial hygiene company, has continued to make progress and has maintained the momentum seen in the second half of last year into the current financial year. The balance sheet continues to remain strong and is well positioned to its objective of positive cash generation at the ear

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.